Minimally-Invasive Secondary Cytoreduction in Recurrent Ovarian Cancer

Certelli, Camilla; Russo, Silvio Andrea; Palmieri, Luca; Foresta, Aniello; Pedone Anchora, Luigi; Vargiu, Virginia; Santullo, Francesco; Fagotti, Anna; Scambia, Giovanni; Gallotta, Valerio

doi:10.3390/cancers15194769

Cited by 4 publications

(1 citation statement)

References 79 publications

(112 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sanna et al reported a case series of MIS nodal relapse asportation up to 8 cm, demonstrating that MIS for ILNR in gynecological malignancies may be a feasible, safe and effective option in terms of oncological outcomes, even for large tumors [40]. Recently, Certelli et al published a review specifically about the role of SCS in the treatment of recurrent ovarian cancer, showing that a minimally invasive approach plays a crucial role in this setting in terms of survival rates and quality of life [41].…”

Section: Discussionmentioning

confidence: 99%

Laparoscopic Treatment of Bulky Nodes in Primary and Recurrent Ovarian Cancer: Surgical Technique and Outcomes from Two Specialized Italian Centers

Daniele,

Rosso,

Ceccaroni

et al. 2024

Cancers

View full text Add to dashboard Cite

(1) Background: Minimally invasive surgery (MIS) represents a feasible approach in early-stage ovarian cancer, while this question is still unsolved for advanced and recurrent disease. (2) Methods: In this retrospective, multicenter study, we present a series of 21 patients who underwent MIS for primitive or recurrent epithelial ovarian cancer (EOC) with bulky nodal metastasis and discuss surgical technique and outcomes in relation to the current literature. (3) Results: Complete cytoreduction at primary debulking surgery was obtained in 86% of cases. No complication occurred in our patients intraoperatively and only 11.1% of our patients experienced grade 2 and 3 postoperative complications. Notably, all the patients with isolated lymph nodal recurrence (ILNR) were successfully treated with a minimally invasive approach with no intra- or postoperative complications. (4) Conclusions: The results of our study are consistent with those reported in the literature, demonstrating that MIS may represent a safe approach in advanced and recurrent EOC with nodal metastasis if performed on selected patients by expert surgeons with an adequate setting and appropriate technique.

show abstract

Section: Discussionmentioning

confidence: 99%

Laparoscopic Treatment of Bulky Nodes in Primary and Recurrent Ovarian Cancer: Surgical Technique and Outcomes from Two Specialized Italian Centers

Daniele,

Rosso,

Ceccaroni

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

Robotic approach for the treatment of gynecological cancers recurrences: A ten-year single-institution experience

Certelli,

Palmieri,

Federico

et al. 2024

European Journal of Surgical Oncology

View full text Add to dashboard Cite

Robotic Recto-Sigmoid Resection with Total Intracorporeal Colorectal Anastomosis (TICA) in Recurrent Ovarian Cancer

Palmieri,

Santullo,

Lodoli

et al. 2024

Ann Surg Oncol

View full text Add to dashboard Cite

Background About 70% of women affected by ovarian cancer experience relapse within 2 years of diagnosis. Traditionally, the standard treatment for recurrent ovarian cancer (ROC) has been represented by systemic chemotherapy.1 Recently, several retrospective studies have suggested that secondary cytoreductive surgery could provide better clinical outcomes than chemotherapy alone, in the case of complete tumor cytoreduction.2,3 About 50% of patients with ROC have a pelvic component of the disease and 22% of patients present isolated pelvic recurrence, often involving the rectum.4,5 Minimally invasive secondary cytoreductive surgery is a feasible option and is associated with favorable perioperative outcomes.6–8 It is crucial to fully explore the peritoneal cavity before starting cytoreductive procedures in order to confirm the absence of carcinomatosis.9 The robotic system facilitates the identification of anatomical structures and makes it easier to perform complex surgical steps in narrow spaces. It also allows the integrated use of surgical tools such as intraoperative ultrasound and indocyanine green application. Methods In this video, we present the case of a 64-year-old woman who experienced a rectal recurrence of ovarian cancer after a platinum-free interval of 12 months. We describe, in a step-by-step manner, the surgical procedure of a robotic rectosigmoid resection with totally intracorporeal colorectal anastomosis (TICA).10–12 Results Robotic secondary cytoreduction with complete gross resection was achieved. The patient did not report any intraoperative or postoperative complications. Final histology confirmed ROC. Conclusion Totally robotic rectosigmoid resection is a feasible option in isolated bowel recurrences. Thanks to continuous technical evolution, robot-assisted surgery has the potential to have a central role in the fight against solid tumors. Integration of multiple pre- and intraoperative technologies allows personalized surgery to be performed for each different patient.13,14

show abstract

Minimally-Invasive Secondary Cytoreduction in Recurrent Ovarian Cancer

Cited by 4 publications

References 79 publications

Laparoscopic Treatment of Bulky Nodes in Primary and Recurrent Ovarian Cancer: Surgical Technique and Outcomes from Two Specialized Italian Centers

Laparoscopic Treatment of Bulky Nodes in Primary and Recurrent Ovarian Cancer: Surgical Technique and Outcomes from Two Specialized Italian Centers

Robotic approach for the treatment of gynecological cancers recurrences: A ten-year single-institution experience

Robotic Recto-Sigmoid Resection with Total Intracorporeal Colorectal Anastomosis (TICA) in Recurrent Ovarian Cancer

Contact Info

Product

Resources

About